Cite
HARVARD Citation
Voorhees, P. et al. (2021). A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). American journal of hematology. 96 (12), pp. 1595-1603. [Online].